The whitepaper focuses on liposomes as a drug space. By protecting the drug substance and changing its release profile, the lipid-based vesicles can enhance efficacy, minimize toxicity and overall improve the profile of the drug product. Yet, only a few companies are equipped to manage the complexities of working with liposomes, making it critical for new drug developers to know what to look for when choosing the right manufacturing partner (CDMO).
CDMOs with the ability to develop liposome-based formulations and their large scale manufacturing are few despite the technology emerging as a key R&D enabler. Find out some of the key questions that you need to ask your potential partners.
